What Happens If You Take Antipsychotics and Don’t Need Them?

Taking antipsychotics when you don’t have the condition they’re designed to treat can alter your brain chemistry, metabolism, hormones, and emotional life in measurable ways. These drugs work by blocking dopamine receptors, and your brain doesn’t check whether you have a psychiatric diagnosis before responding to that blockade. Research on healthy volunteers, and on people prescribed antipsychotics off-label for sleep or behavior problems, shows a consistent pattern of side effects that range from sluggish thinking and emotional flattening to insulin resistance and hormonal disruption.

Why People Without Psychosis End Up on Antipsychotics

The question isn’t hypothetical. Millions of prescriptions for antipsychotics go to people who don’t have schizophrenia, bipolar disorder, or any psychotic illness. Quetiapine (sold as Seroquel) is one of the most commonly prescribed antipsychotics off-label, particularly for insomnia.¹ Low doses are handed out for sleep trouble, anxiety, and agitation, often in people who have never experienced psychosis. In children and adolescents, antipsychotics are prescribed off-label for behavior problems associated with ADHD, especially when a disruptive behavior disorder is also present.² Older adults with dementia are another large group receiving antipsychotics for symptoms like agitation that aren’t psychotic in nature.

The concern with all of these scenarios is the same: the drug is still doing the same thing to the brain regardless of the reason it was prescribed. When a drug’s primary action is to dampen dopamine signaling, the downstream consequences don’t care whether the prescription was for schizophrenia or for trouble sleeping.

Your Thinking Slows Down

One of the most well-documented effects of antipsychotics in healthy people is impaired working memory, the mental workspace you use to hold and manipulate information in real time. A rigorous study gave healthy volunteers either amisulpride, aripiprazole, or a placebo over several days and tested their cognitive performance. Both drugs significantly impaired working memory compared to placebo. The impairment showed up specifically as slower response times rather than less accurate answers, meaning the brain could still get to the right answer but took longer to get there.³ The researchers ruled out generalized drowsiness or motor impairment as explanations, concluding that dopamine receptor blockade specifically interferes with working memory function.

This finding is especially notable because amisulpride and aripiprazole work through somewhat different mechanisms: one blocks dopamine D2/D3 receptors outright, and the other partially activates them. Yet both produced similar cognitive slowdowns. The study’s authors described this as the first causal evidence in healthy humans that working memory is impaired by antipsychotic-level dopamine manipulation.⁴

An earlier study using a single dose of amisulpride painted a somewhat different picture, finding improvement on a word fluency test, though the authors noted that practice effects might have contributed to some of the positive results on computerized tests.⁵ The discrepancy between a single dose and sustained use matters: a one-time dose may briefly tweak dopamine levels in a way that momentarily helps certain tasks, while continued use produces the persistent cognitive slowdown seen in the longer study. For someone taking an antipsychotic they don’t need over weeks or months, the sustained pattern of impairment is the more relevant finding.

Emotional Responses Get Muted

Beyond thinking speed, antipsychotics can flatten your emotional landscape. A placebo-controlled experiment gave healthy volunteers amisulpride and then showed them emotionally charged images. Compared to placebo, the amisulpride group rated pleasant images as less positive, and their physiological arousal responses (measured through skin conductance) were diminished across the board, with the blunting especially pronounced for pleasant stimuli.⁶ The researchers interpreted this as evidence that D2 blockade can reduce hedonic responsivity, or the ability to feel pleasure in the moment.

This is not subtle. If you’ve ever heard someone on antipsychotics describe feeling “flat” or “zombied out,” this experimental data puts a neurochemical basis under that subjective experience. In people with active psychosis, this emotional dampening may be a worthwhile trade-off for relief from hallucinations or delusions. In someone without psychosis, you’re paying the cost without getting the intended benefit. The blunting wasn’t limited to negative emotions either: it specifically reduced how good the good things felt. That can affect motivation, social engagement, and general quality of life.

Metabolic Disruption Starts Fast and Doesn’t Require Weight Gain

One of the most insidious effects of antipsychotics in people who don’t need them is metabolic. A study in healthy volunteers found that olanzapine caused significant insulin resistance along with disrupted postprandial hormone signaling, including elevated insulin, GLP-1, and glucagon after meals. Aripiprazole also induced insulin resistance, though without the same hormonal disruption. The critical finding was that these metabolic changes happened without any weight gain, without increased food intake or hunger, and obviously without any psychiatric disease being present.⁷

This challenges a common assumption that antipsychotic-related metabolic problems are mainly a downstream result of the weight gain these drugs can cause. The evidence shows the drugs directly affect how your tissues handle glucose, independent of appetite or body weight. For someone taking a low dose of quetiapine for sleep or a short course of aripiprazole for anxiety, this means metabolic risk begins with the first prescription, not after months of weight gain.

Hormonal Side Effects You Might Not Connect to the Drug

Antipsychotics are the primary medications implicated in abnormally elevated prolactin levels, a condition called hyperprolactinemia that occurs in up to about 70% of people taking these drugs. Some agents are worse than others: risperidone has the highest prevalence, with studies monitoring for this effect reporting it in 70% to 100% of patients.⁸ The downstream effects of elevated prolactin are broad. In both men and women, it can cause sexual dysfunction, infertility, and breast milk production unrelated to pregnancy. Over time, elevated prolactin suppresses sex hormones, which can lead to decreased bone mineral density, osteoporosis, and fractures.

These are not rare curiosities. If you’re a young woman prescribed quetiapine for insomnia and you start experiencing missed periods or unexplained breast discharge, or a man experiencing reduced libido and fatigue, the antipsychotic may be the cause. These symptoms often get attributed to other things because neither the patient nor the prescriber is thinking about the hormonal footprint of the drug, especially when it was prescribed for a non-psychiatric condition.

What Prolonged Use Does to Your Brain

Long-term antipsychotic use rewires the brain’s dopamine system in ways that can outlast the prescription. Studies on cell cultures and animal models have shown that sustained antipsychotic exposure leads to an upregulation of dopamine D2 receptors in the striatum along with enhanced receptor sensitivity to dopamine.⁹ In plain terms, when you block dopamine receptors with a drug, the brain compensates by making more receptors and making them more sensitive. This is the brain’s attempt to restore normal dopamine signaling despite the chemical blockade.

The problem surfaces when the drug is stopped. Those extra, supersensitive receptors are suddenly flooded with dopamine that’s no longer being blocked. In patients who do have a psychotic illness, this can trigger what’s called supersensitivity psychosis: a rebound of symptoms that is worse than the original condition and harder to treat.¹⁰ In someone who never had psychosis to begin with, the concern is different but still real: abruptly stopping an antipsychotic after long-term use can produce rebound insomnia, agitation, and anxiety that feels worse than whatever the drug was originally prescribed for. This can trap people in a cycle where they feel unable to stop the medication.

There are structural concerns as well. A landmark study in macaque monkeys found that chronic exposure to either haloperidol or olanzapine resulted in an 8 to 11% reduction in brain weight, affecting both grey and white matter. A longitudinal study in humans provided further support, finding that greater intensity of antipsychotic treatment was associated with progressive reductions in brain volume over time.¹¹ The interpretation of these findings is complicated, because the illness itself (particularly schizophrenia) also causes brain volume loss. A neuroimaging study in people with first-episode psychosis attempted to tease apart the two effects by randomizing patients to antipsychotic medication or placebo. The results showed that the drug and the illness exerted distinct and spatially different effects on brain volume. In some regions, the antipsychotic actually increased volume in ways associated with symptom improvement, while other changes appeared to be drug-related rather than illness-related.¹²

For someone without psychosis, the protective effects that antipsychotics may exert on an actively psychotic brain aren’t relevant. What remains is the possibility of drug-driven structural changes without the compensating therapeutic benefit. The evidence here is still evolving, and the human data comes almost entirely from patients with psychiatric illness, making direct extrapolation to healthy brains uncertain. But it’s enough to take seriously when weighing risks in someone who doesn’t have a clear psychiatric indication.

Serious Risks in Older Adults

The stakes escalate sharply for elderly people, especially those with dementia. Antipsychotics carry a regulatory black box warning about increased mortality risk in older adults with dementia-related psychosis. A large population-based study found that antipsychotic use in people with dementia was associated with elevated risks of pneumonia (roughly double the risk compared to non-users), stroke (about 60% higher risk), acute kidney injury, venous blood clots, fractures, heart attack, and heart failure.¹³ These risks applied during current use and were elevated across nearly every adverse outcome the researchers measured.

The inappropriate prescribing of antipsychotics to elderly people has been flagged as a major public health problem. A report established that such patients faced roughly an 85% increased risk of adverse events and greater mortality.¹⁴ For an older adult prescribed quetiapine for nighttime agitation who doesn’t have a psychotic disorder, the risk profile is dramatically different from that of a younger adult taking the same dose. Falls, pneumonia, and stroke are already leading causes of death and disability in this age group, and antipsychotics make every one of them more likely.

What Happens in an Overdose

Accidental or intentional overdose on antipsychotics is a distinct concern, especially when the drugs are prescribed casually or stockpiled by people who take them intermittently for sleep. The most serious effects of overdose involve the cardiovascular and central nervous systems. Sedation is the most common feature, and it can be profound. The most common cardiovascular problems are rapid heart rate, low blood pressure, and prolongation of the heart’s electrical cycle, known as QTc prolongation.¹⁵ Other possible complications include seizures and a rare but life-threatening condition called neuroleptic malignant syndrome, which involves fever, muscle rigidity, and autonomic instability. No antidotes exist for antipsychotic poisoning, though most cases respond to supportive care.

A systematic review of cardiovascular effects following atypical antipsychotic overdose found that dangerous heart rhythm disturbances and cardiovascular death were rare, even in overdose.¹⁶ That’s relatively reassuring compared to older-generation antipsychotics, but it doesn’t mean overdose is safe. Consensus guidelines note that anyone who is drug-naive and experiencing symptoms beyond mild drowsiness should be taken to an emergency department. For children under 12 who have never taken antipsychotics before, thresholds for emergency evaluation are quite low: as little as 50 mg of clozapine, 10 mg of olanzapine, or 1 mg of risperidone warrants medical attention if the child has ingested more than the specified cutoff and is not already under observation.¹⁷

The Gray Area of Off-Label Sleep and Anxiety Prescribing

A lot of the real-world concern about unnecessary antipsychotic use centers on low-dose quetiapine prescribed for insomnia or generalized anxiety. These prescriptions represent the most common way that someone without psychosis ends up on an antipsychotic. A systematic review and meta-analysis of clinical trials found that quetiapine does improve sleep quality compared to placebo, but also that adverse events and discontinuation due to adverse events were common among quetiapine users.¹⁸ The drug is sedating, and it does help people fall asleep. But the sedation is a side effect repurposed as a feature, and it comes packaged with the full range of metabolic, hormonal, and neurological effects described above.

The trade-off is very different from what you’d accept for treating psychosis. For schizophrenia, antipsychotics can be the difference between functional life and disability. The side effects, while real, are weighed against an illness that can be devastating. For insomnia, you’re accepting all the same side effect risk to address a condition that has multiple alternative treatments: cognitive behavioral therapy for insomnia, sleep hygiene changes, and other medications with narrower side effect profiles. The calculus shifts even further when you consider that the dopamine supersensitivity described earlier can make the insomnia worse after you stop the drug, creating a dependency loop that had no reason to exist.

Individual Variation in Drug Metabolism

Not everyone processes antipsychotics at the same rate. Genetic differences in liver enzymes, particularly CYP2D6 and CYP2C19, mean that some people are “poor metabolizers” who break down these drugs much more slowly than average. For those individuals, a standard dose produces higher and longer-lasting blood levels of the drug, amplifying every side effect. Someone who is a poor metabolizer taking a low dose of quetiapine for sleep might effectively be getting the equivalent of a much higher dose, with correspondingly stronger metabolic, cognitive, and hormonal effects.

Pharmacogenomic testing can identify people who fall into these metabolizer categories before prescribing, but it is not routinely ordered in most clinical settings, especially for off-label prescriptions. This means a subset of people taking antipsychotics they don’t strictly need are experiencing side effects that are disproportionate to their dose, and neither they nor their doctors know why. If you’ve been prescribed an antipsychotic off-label and find the side effects unexpectedly intense, slow metabolism is one explanation worth investigating with your prescriber.

How Antipsychotics Differ From Each Other

Talking about “antipsychotics” as a single category oversimplifies things. The metabolic study described earlier found that olanzapine and aripiprazole both caused insulin resistance in healthy people, but olanzapine also disrupted a wider range of postprandial hormones while aripiprazole did not.⁷ Risperidone has the highest rate of prolactin elevation, while aripiprazole and quetiapine are considered less likely to cause that particular problem.⁸ The cognitive impairment data comes from amisulpride and aripiprazole, which represent two different pharmacological approaches that nonetheless produced similar slowing of working memory.

The point is that switching from one antipsychotic to another might reduce a specific side effect but won’t eliminate the fundamental problem: these drugs all modulate dopamine signaling in ways that have consequences for a brain that doesn’t have a dopamine-related disorder. The choice among them involves trade-offs in which side effects you’re likely to get, not whether you’ll get them. For someone without psychosis weighing whether to stay on an antipsychotic, the relevant question is often not “which antipsychotic is safest” but “do I need to be on one at all.”